832 Results

People

  1. Pfister
    Pfister
  2. Lee
    Lee
  3. Sherman
    Sherman
  4. Riaz
    Riaz
  5. Dunn
    Dunn
  6. Wong
    Wong
  7. Ho
    Ho
  8. McBride
    McBride
  9. Shah
    Shah
  10. Tsai
    Tsai

Groups

  1. Head and Neck Service (832)
  2. Solid Tumor Oncology Division (832)
  3. Department of Medicine (826)
  4. Surgery (358)
  5. Radiation Oncology, Department of (310)
  6. Survivorship Research (310)
  7. Center for Pancreatic Cancer Research (173)
  8. Epidemiology and Biostatistics (162)
  9. Weinberg Fellows (161)
  10. Department of Pathology and Laboratory Medicine (155)
  1. "Head and Neck Service"
Formats
  1. Journal Article (407)
  2. Meeting Abstract (360)
  3. Book Section (20)
  4. Review (19)
  5. Editorial (7)
  6. Guidelines (7)
  7. Research Letter (6)
  8. Correspondence (3)
  9. Book Whole (1)
  10. Conference Paper (1)
  11. Miscellaneous (1)
Groups
  1. Head and Neck Service (832)
  2. Solid Tumor Oncology Division (832)
  3. Department of Medicine (826)
  4. Surgery (358)
  5. Radiation Oncology, Department of (310)
  6. Survivorship Research (310)

More Groups

People
  1. David Pfister (389)
  2. Eric Sherman (339)
  3. Nancy Lee (266)
  4. Alan Ho (238)
  5. Nadeem Riaz (159)
  6. Lara Dunn (141)

More People

Years
  1. 2025 (12)
  2. 2024 (72)
  3. 2023 (55)
  4. 2022 (57)
  5. 2021 (58)
  6. 2020 (66)

More Years

Publications
  1. Journal of Clinical Oncology (205)
  2. International Journal of Radiation Oncology, Biology, Physics (140)
  3. Annals of Oncology (43)
  4. Cancer (33)
  5. Head & Neck (28)
  6. Journal of the National Comprehensive Cancer Network (28)

More Publications

Publishers
  1. American Society of Clinical Oncology (219)
  2. Elsevier Inc. (176)
  3. Wiley Blackwell (55)
  4. Oxford University Press (53)
  5. American Association for Cancer Research (46)
  6. Harborside Press (28)

More Publishers

Results (832)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Selpercatinib-induced hypothyroidism through off-target inhibition of type 2 iodothyronine deiodinase
    Journal Article

    Boucai, L.; Salas-Lucia, F.; Krishnamoorthy, G. P.; Sherman, E.; Rudin, C. M.; Drilon, A.; Bianco, A. C.; Fagin, J. A.
    JCO Precision Oncology (2022)

    Fulltext@MSK | Save
  • A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
    Meeting Abstract

    Chung, C.; Colevas, D.; Adkins, D.; Park, J. C.; Rodriguez, C.; Gibson, M.; Sukari, A.; Burtness, B.; Johnson, F.; Julian, R.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Cytotoxic revival is implicated in response to neoadjuvant PD-1 blockade for head and neck squamous cell carcinoma
    Meeting Abstract

    Afeyan, A.; Oliveira, G.; Egloff, A. M.; Zeng, Z.; Chernock, R.; Zhou, L.; Messier, C.; Lizotte, P.; Wolff, J.; Pfaff, K.; more...
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • A phase 1/2 trial to evaluate the safety and antitumor activity of tipifarnib and alpelisib for patients with HRAS-overexpressing and/or PIK3CA-mutated/amplified recurrent/metastatic head and neck squamous cell carcinoma (The KURRENT trial)
    Meeting Abstract

    Hanna, G. J.; Batista, C. P.; Ho, A. L.; Gillison, M. L.; Adkins, D.; Dayoub, A.; Martell, B.; Leoni, M.; Dale, S.; Nie, K.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • PTEN loss-of-function mutations prevalent in HRAS-mutant cancers results in resistance to targeted therapy
    Meeting Abstract

    Nigam, A.; Chatila, W. K.; Krishnamoorthy, G. P.; Ho, A. L.; Fagin, J. A.; Schultz, N. D.; Untch, B. R.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): Update of the LIBRETTO-001 trial
    Meeting Abstract

    Kroiss, M.; Sherman, E.; Wirth, L. J.; Cabanillas, M. E.; Robinson, B.; Subbiah, V.; Drilon, A.; Godbert, Y.; Fasnacht, N.; Soldatenkova, V.; more...
    Swiss Medical Weekly (2022)

    Fulltext@MSK | Save
  • Phase II study of enzalutamide for patients with androgen receptor-positive salivary gland cancers (Alliance A091404)
    Journal Article

    Ho, A. L.; Foster, N. R.; Zoroufy, A. J.; Campbell, J. D.; Worden, F.; Price, K.; Adkins, D.; Bowles, D. W.; Kang, H. Y. S.; Burtness, B.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update
    Meeting Abstract

    Sherman, E.; Wirth, L.; Shah, M.; Cabanillas, M.; Robinson, B.; Italiano, A.; Laskin, J.; Subbiah, V.; Drilon, A.; Wright, J.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): Update of the LIBRETTO-001 trial
    Meeting Abstract

    Kroiss, M.; Sherman, E. J.; Wirth, L. J.; Cabanillas, M. E.; Robinson, B.; Subbiah, V.; Drilon, A. E.; Godbert, Y.; Fasnacht, N.; Soldatenkova, V.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Phase II study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (CSCC): Final analysis from EMPOWER-CSCC-1 groups 1, 2 and 3
    Meeting Abstract

    Migden, M. R.; Schmults, C.; Khushanlani, N.; Guminski, A.; Chang, A. L.; Lewis, K.; Ansstas, G.; Bowyer, S. E.; Hughes, B. G. M.; Schadendorf, D.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save